Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Levis

Showing results (11-20 of 107) with videos related to

Pageof 11
Sort By:
Clinical Advances in Hematology & Oncology : H&O|February 13, 2014
Quizartinib in acute myeloid leukemiaMark Levis
Blood|May 19, 2011
FLT3/ITD AML and the law of unintended consequencesMark Levis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2012
Phospho-specific flow: fixating on the targetMark Levis
Hematology. American Society of Hematology. Education Program|December 5, 2025
Post-HCT maintenance therapy for AML: who, when, why, how long?Mark Levis
Blood|October 13, 2022
By any other name …Mark Levis
Best Practice & Research. Clinical Haematology|March 25, 2021
Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?Mark Levis
Future Oncology (London, England)|August 23, 2014
Quizartinib for the treatment of FLT3/ITD acute myeloid leukemiaMark Levis
American Journal of Hematology|February 1, 2017
FLT3 as a marker of minimal residual disease: Time to re-think?Mark Levis
Current Opinion in Hematology|January 20, 2011
FLT3 inhibitors: a story of the old and the newAmir Fathi, Mark Levis
Expert Opinion on Investigational Drugs|December 4, 2003
Novel FLT3 tyrosine kinase inhibitorsMark Levis, Donald Small
Pageof 11

Showing results (11-20 of 107) with videos related to

Sort By:
Pageof 11
Clinical Advances in Hematology & Oncology : H&O|February 13, 2014
Quizartinib in acute myeloid leukemiaMark Levis
Blood|May 19, 2011
FLT3/ITD AML and the law of unintended consequencesMark Levis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2012
Phospho-specific flow: fixating on the targetMark Levis
Hematology. American Society of Hematology. Education Program|December 5, 2025
Post-HCT maintenance therapy for AML: who, when, why, how long?Mark Levis
Blood|October 13, 2022
By any other name …Mark Levis
Best Practice & Research. Clinical Haematology|March 25, 2021
Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?Mark Levis
Future Oncology (London, England)|August 23, 2014
Quizartinib for the treatment of FLT3/ITD acute myeloid leukemiaMark Levis
American Journal of Hematology|February 1, 2017
FLT3 as a marker of minimal residual disease: Time to re-think?Mark Levis
Current Opinion in Hematology|January 20, 2011
FLT3 inhibitors: a story of the old and the newAmir Fathi, Mark Levis
Expert Opinion on Investigational Drugs|December 4, 2003
Novel FLT3 tyrosine kinase inhibitorsMark Levis, Donald Small
Pageof 11